A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2022
The main purpose of this study is to compare the clinical benefit, as measured by Progression‐Free Survival (PFS) and Overall Survival(OS), achieved by HX008 Plus Transcatheter Arterial Chemoembolization (TACE) or Temozolomide Plus Transcatheter Arterial Chemoembolization (TACE) in the First‐Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver.
Epistemonikos ID: aa14900f06df3e5d07fbd6f5c05acac2fac804ef
First added on: May 14, 2024